Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion

Journal of Surgical Oncology

Volumn 109, Issue 5, 2014, Pages 405-409

  Steinman, Jonathan ^a   Ariyan, Charlotte ^a   Rafferty, Brian ^a   Brady, Mary S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

limb tumor burden; Merkel cell carcinoma; recurrent melanoma; soft tissue sarcoma

Indexed keywords

DACTINOMYCIN; MELPHALAN; PAPAVERINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; ISOLATED LIMB INFUSION; LIMB AMPUTATION; LIMB PAIN; LIMB SALVAGE; LIMB TUMOR; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MERKEL CELL TUMOR; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; REGIONAL PERFUSION; SOFT TISSUE SARCOMA; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VERY ELDERLY;

LIMB TUMOR BURDEN; MERKEL CELL CARCINOMA; RECURRENT MELANOMA; SOFT TISSUE SARCOMA;

ADULT; AGED; AMPUTATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, MERKEL CELL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACTINOMYCIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EXTREMITIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIMB SALVAGE; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SARCOMA; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84897026998     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23519     Document Type: Article

References (17)

1. Thompson JF, Kam PC, Waugh RC, et al.: Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238-247.
2. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123-1129.
3. Brady MS, Brown K, Patel A, et al.: Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: Final report of a phase II clinical trial. Melanoma Res 2009; 19: 106-111.
4. Lindner P, Doubrovsky A, Kam PC, et al.: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127-136.
5. Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
6. Karakousis CP, Balch CM, Urist MM, et al.: Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3: 446-452.
7. Balch CM, Soong SJ, Smith T, et al.: Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-108.
8. Ariyan CE, Brady MS:, History of regional chemotherapy for cancer of the extremities. Int J Hyperthermia 2008; 24: 185-192.
9. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
10. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
11. Cornett WR, McCall LM, Petersen RP, et al.: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196-4201.
12. Shetty G, Beasley GM, Sparks S, et al.: Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol 2013; 20: 1128-1135.
13. Barbour AP, Thomas J, Suffolk J, et al.: Isolated limb infusion for malignant melanoma: Predictors of response and outcome. Ann Surg Oncol 2009; 16: 3463-3472.
14. Raymond AK, Beasley GM, Broadwater G, et al.: Current trends in regional therapy for melanoma: Lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 2011; 213: 306-316.
15. Alexander HR, Jr, Fraker DL, Bartlett DL, et al.: Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28: 114-118.
16. Beasley GM, Caudle A, Petersen RP, et al.: A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 2009; 208: 706-715; discussion 715-717.
17. Kroon HM, Moncrieff M, Kam PC, et al.: Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008; 15: 3003-3013.